PrecisionLife Limited announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the company's UK headquarters in Oxfordshire, UK.

Stubberfield brings over three decades experience in leading drug discovery research in the life sciences industry. At PrecisionLife he will be responsible for developing the company's pipeline of partnered and in-house discovery programs, validating novel precision therapies and biomarkers, and managing the growing biopharma team and its collaborations with external partners and CROs.

He joins from e-Therapeutics where he was Chief Research Officer, leading the Company's small molecule drug discovery projects. Colin has built virtual development models, bringing together resources from CROs and in collaboration with pharma partners. He has coordinated diverse teams in successful target identification/validation and drug discovery organizations, from large pharma to small biotechs, including UCB-Celltech, Oxford GlycoSciences, GSK and Wellcome.

Welcoming Colin to the company, Steve Gardner, CEO of PrecisionLife, said: "Together with our recent financing, Colin's appointment is a key step to making the transition from an AI R&D services company to a precision medicine drug discovery and healthcare focused company driven by our deep understanding of the biology that causes disease in key patient subgroups, and a rapidly growing pipeline of partnered and in-house programs of novel precision therapies and biomarkers."